Ds Healthcare Group Inc (DSKX) 1.15 $DSKX
DS Healthcare Group obtains regulatory sales approval in Middle East, reflecting 6% of the worldwide market
M2 - Fri Sep 05, 4:53AM CDT
Topical therapies company DS Healthcare Group reported on Thursday the receipt of regulatory approval for the sale of its products line in Middle East following its recent expansion into Brazil and China.
DS Healthcare Group obtains regulatory approval in Middle East
GlobeNewswire - Thu Sep 04, 7:26AM CDT
This agreement comes on the heels of the Company's recent expansion into Brazil and China. International sales are a key driver of the Company's growth, as its breakthrough products are in high demand in Canada, Mexico, the UK, and Australia.
DS Healthcare Group to Open its First DS Laboratories Hair Loss Clinic Offering Patients Unique Personalized Therapies for Hair Loss
GlobeNewswire - Tue Sep 02, 7:07AM CDT
DS Healthcare Group, Inc. (NASDAQ: DSKX), a leading developer of personal care products and specialty pharmaceuticals, today announced it will open its first DS Laboratories Hair Loss Clinic in Miami, Florida. Slated to open in the fourth quarter of 2014, the clinic will provide unique therapies and treatment options for patients who desire the most comprehensive approach to treating hair loss. A team of healthcare professionals led by a medical doctor will provide customized solutions with the most advanced proven technologies developed through DS Healthcare's clinical research to restore a full head of hair.
DS Healthcare Group (DSKX) is Undervalued With Good Seasonality.
M2 - Fri Aug 22, 7:27AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has updated its research report today on DS Healthcare Group (NASDAQ: DSKX). The report highlights the short term bullish seasonality that has emerged, the SqueezeTrigger Price of $2.51 and the projected fundamental valuation of $5.50 per share.
BUYINS.NET Issues DS Healthcare Group (DSKX) SqueezeTrigger Report
M2 - Fri Aug 15, 7:20AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on DS Healthcare Group (NASDAQ: DSKX) after releasing the latest short sale data through August 13, 2014. The total aggregate number of shares shorted since May 2010 is approximately 2.08 million shares. Approximately 30% of daily trading volume is short selling. The SqueezeTrigger price for all DSKX shares shorted is $2.51. A short squeeze is expected to begin when shares of DSKX close above the $2.51 SqueezeTrigger price.
DS Healthcare Group Reports Second Quarter 2014 Financial Results
GlobeNewswire - Fri Aug 15, 7:15AM CDT
DS Healthcare Group, Inc. (NASDAQ: DSKX), a leading developer of personal care products, today announced financial results for the three and six months ended June 30, 2014.
DS Healthcare signs third distribution agreement in Brazil for personal care products
M2 - Thu Aug 07, 4:11AM CDT
Specialist pharmaceuticals company DS Healthcare Group (NasdaqCM
SKX) announced on Wednesday that it signed a distribution agreement the Rio de Janerio-based wholesale pharmacy Drogaria Venancio.
DS Healthcare Expands Distribution Channels in Brazil Through Leading Rio de Janeiro Pharmacy Chain
GlobeNewswire - Wed Aug 06, 7:43AM CDT
DS Healthcare Group, Inc. (NASDAQ: DSKX), a leading developer of personal care products and specialty pharmaceuticals, announced today it has signed a distribution agreement with Drogaria Venancio, a leading Rio de Janerio-based pharmacy chain. Drogaria Venancio will sell DS Healthcare's clinically proven personal care products including its Revita and Spectral hair re-growth and hair care products. DS Laboratories, its flagship line can already be found on retail shelves throughout Rio de Janeiro. Drogaria Venancio operates wholesale distribution centers and premium retail pharmacy locations. Founded in 1979, the pharmacy chain employs 1600 people.
Global Anti-Aging Product Market 2014-2018 - Skincare Products, Cosmeceuticals, and Hair Care Products
M2 - Wed Jul 16, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7slrvw/global_antiaging) has announced the addition of the "Global Anti-Aging Product Market 2014-2018" report to their offering. The Global Anti-aging Product market will grow at a CAGR of 6.77 percent over the period 2013-2018. Aging is associated with numerous common health problems. Anti-aging products help in fighting the various signs of aging or problems such as wrinkles, blemishes, dry lines, fine color, pores, graying, thinning, and sagging. To overcome these aging problems related to skin and hair consumers use many products that basically fall under three categories: skincare, cosmeceuticals, and hair care. The Global Anti-aging Product market can be divided into three segments: Skincare Products, Cosmeceuticals, and Hair Care Products. These are the product categories used by consumers to reduce various signs of aging and maintain youthfulness. The report, the Global Anti-aging Product Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Anti-aging Product market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Beiersdorf AG - L'Or?al SA - Phosphagenics Ltd. - Procter & Gamble Co. - Unilever Group Other Prominent Vendors - Allergan Inc. - Amexdrug Corp. - Avon Products Inc. - Chanel SA - Christian Dior SA - Clarins USA Inc. - DS Healthcare Group Inc. - Elizabeth Arden Inc. - Ella Bach? - Est?e Lauder Co. Inc. - Henkel AG & Co KGaA - Jan Marini Skin Research Inc. - Johnson & Johnson Co. - Kao Corp. - NeoStrata Co. - NuSKin Enterprises - Orlane SA - Revlon Inc. - Robanda International Inc. - Shiseido Co. - SkinMedica Inc. - Skinvisible Inc. - Woodridge Labs Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Demographic Segmentation - Market Segmentation by Product - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/7s..._antiaging
DS Healthcare Appoints Mark Wolfson to its Board of Directors
GlobeNewswire - Wed Jul 16, 7:00AM CDT
DS Healthcare Group, Inc.(NASDAQ: DSKX), a leading developer of personal care products and specialty pharmaceuticals, announced today that Mark Wolfson has joined its Board as an Independent Director and will serve on the Company's Audit Committee, and its Nominating and Corporate Governance Committee.
DS Healthcare Opens its First DS Laboratories Store in China
GlobeNewswire - Mon Jul 14, 7:00AM CDT
DS Healthcare Group, Inc. (NASDAQ: DSKX), a leading developer of personal care products and specialty pharmaceuticals, announced today that the first DS Laboratories store worldwide has opened in Shanghai, China in partnership with the Company's Chinese distributor. The store exclusively features a complete line of DS Healthcare products including the Company's clinically proven, industry-leading Spectral line of hair loss treatments and Revita hair stimulating shampoos and conditioners. The Company plans to open additional partnership stores worldwide in the coming months.
DS Healthcare Group to Open its First Retail Boutique as Part of Global Brand Strategy
GlobeNewswire - Thu Feb 27, 8:52AM CST
DS Healthcare Group, Inc. (NASDAQ: DSKX), a leading developer of personal care products, today announced it is in the process of opening its first DS Laboratories retail store scheduled to open in the third quarter of 2014. The store, to be located in the metro Miami area, will showcase DS Healthcare's line of products including its industry-leading Spectral line of hair loss treatments and Revita hair stimulating shampoo and conditioner. The move is part of the Company's broader strategy as it continues to build the premier global brand in clinically proven personal care products.
DS Healthcare Group Signs Agreement with Leading Global Healthcare Company
GlobeNewswire - Mon Feb 10, 7:02AM CST
DS Healthcare Group, Inc. (NASDAQ SKX), a leading developer of personal care products, today announced it has signed an agreement with a global healthcare company that ranks in the top 200 of the Fortune Global 500 list of largest corporations in the world in 2013. Per the terms of the agreement, DS Healthcare is providing the formulation, ingredients and its technology to the global healthcare company for use in a topical product. The product is to be launched and distributed by the global healthcare company under their own brand following successful development. Under the terms of the agreement, DS Healthcare will act as the exclusive ingredient supplier for a period of 5 years, which will automatically renew under certain conditions.
DS Healthcare Group Moves Prescription Hair Loss Treatment Forward with Appointment of Aptiv Solutions as CRO
GlobeNewswire - Mon Jan 27, 7:00AM CST
DS Healthcare Group, Inc. (NASDAQ SKX), a leading developer of personal care products, today announced it has appointed Aptiv Solutions as its clinical research organization (CRO) for its proprietary topical prescription treatment. If approved the drug will be positioned as frontline therapy in the fight against hair loss, a condition that affects nearly half of the population.
DS Healthcare Group Prepares to File Investigational New Drug Application with FDA for Prescription Hair Loss Treatment
GlobeNewswire - Thu Jan 09, 7:00AM CST
DS Healthcare Group, Inc.(NASDAQ SKX), a leading developer of personal care products, today announced it is preparing to submit to the United States Food and Drug Administration (FDA) an Investigational New Drug Application (IND) for its proprietary topical hair loss treatment. On October 29, 2013 the Company had announced it filed a patent with the United States Patent and Trademark Office for the invention. An IND is a request for the FDA's authorization to administer an investigational drug to humans and is the first step towards designing and conducting clinical trials in the U.S. DS Healthcare is currently in late stage discussions with various clinical research organizations (CROs) to design and conduct clinical trials for its breakthrough hair loss treatment.
DS Healthcare Group Inc concludes USD3.144m private placement
M2 - Tue Jan 07, 7:55AM CST
Personal care products company DS Healthcare Group Inc (Nasdaq SKX) announced on Monday the sale of 1,965,000 common shares for gross proceeds of USD3.144m to a group of accredited investors in a securities purchase agreement.
DS Healthcare Group Completes Private Placement of $3,144,000 Dollars
GlobeNewswire - Mon Jan 06, 7:01AM CST
DS Healthcare Group, Inc. (Nasdaq: DSKX), a developer of personal care products, today announced that it has completed its securities purchase agreement with a group of accredited investors for the sale of 1,965,000 shares of the Company's common stock, with gross proceeds of $3,144,000. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS) acted as the placement agent in connection with the offering.
DS Healthcare Group, Inc. to Present at the Aegis Capital Corporation 2013 Healthcare Conference
GlobeNewswire - Thu Sep 19, 11:30AM CDT
DS Healthcare Group, NASDAQ (DSKX) announced today that Daniel Khesin, DS Healthcare's CEO, will present at the at the Aegis Capital Corporation 2013 Healthcare Conference on Saturday, September 28, 2013 at 11:00 AM PDT. The conference will be held at the Encore at Wynn Las Vegas on September 26-28, 2013.
DS Healthcare Group Launches Brazilian E-Commerce Site to Support Sales Momentum in Fast Growing Beauty Market
GlobeNewswire - Wed Sep 11, 12:00PM CDT
DS Healthcare Group, Inc. (NASDAQ SKX), a leading developer of personal care products, today announced it has launched its Brazilian website: http://dslabshop.com.br. The e-commerce site provides convenient online shopping for Brazilians. The site also offers extensive product information to support in-stores sales of its products.
OTC Daily Alert Stock Watch - DS Healthcare Group, Inc., (NASDAQ: DSKX)
WorldStockWire - Fri Aug 30, 12:30AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
DS Healthcare Group obtains regulatory sales approval in Middle East, reflecting 6% of the worldwide market
M2 - Fri Sep 05, 4:53AM CDT
Topical therapies company DS Healthcare Group reported on Thursday the receipt of regulatory approval for the sale of its products line in Middle East following its recent expansion into Brazil and China.
DS Healthcare Group obtains regulatory approval in Middle East
GlobeNewswire - Thu Sep 04, 7:26AM CDT
This agreement comes on the heels of the Company's recent expansion into Brazil and China. International sales are a key driver of the Company's growth, as its breakthrough products are in high demand in Canada, Mexico, the UK, and Australia.
DS Healthcare Group to Open its First DS Laboratories Hair Loss Clinic Offering Patients Unique Personalized Therapies for Hair Loss
GlobeNewswire - Tue Sep 02, 7:07AM CDT
DS Healthcare Group, Inc. (NASDAQ: DSKX), a leading developer of personal care products and specialty pharmaceuticals, today announced it will open its first DS Laboratories Hair Loss Clinic in Miami, Florida. Slated to open in the fourth quarter of 2014, the clinic will provide unique therapies and treatment options for patients who desire the most comprehensive approach to treating hair loss. A team of healthcare professionals led by a medical doctor will provide customized solutions with the most advanced proven technologies developed through DS Healthcare's clinical research to restore a full head of hair.
DS Healthcare Group (DSKX) is Undervalued With Good Seasonality.
M2 - Fri Aug 22, 7:27AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has updated its research report today on DS Healthcare Group (NASDAQ: DSKX). The report highlights the short term bullish seasonality that has emerged, the SqueezeTrigger Price of $2.51 and the projected fundamental valuation of $5.50 per share.
BUYINS.NET Issues DS Healthcare Group (DSKX) SqueezeTrigger Report
M2 - Fri Aug 15, 7:20AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on DS Healthcare Group (NASDAQ: DSKX) after releasing the latest short sale data through August 13, 2014. The total aggregate number of shares shorted since May 2010 is approximately 2.08 million shares. Approximately 30% of daily trading volume is short selling. The SqueezeTrigger price for all DSKX shares shorted is $2.51. A short squeeze is expected to begin when shares of DSKX close above the $2.51 SqueezeTrigger price.
DS Healthcare Group Reports Second Quarter 2014 Financial Results
GlobeNewswire - Fri Aug 15, 7:15AM CDT
DS Healthcare Group, Inc. (NASDAQ: DSKX), a leading developer of personal care products, today announced financial results for the three and six months ended June 30, 2014.
DS Healthcare signs third distribution agreement in Brazil for personal care products
M2 - Thu Aug 07, 4:11AM CDT
Specialist pharmaceuticals company DS Healthcare Group (NasdaqCM
SKX) announced on Wednesday that it signed a distribution agreement the Rio de Janerio-based wholesale pharmacy Drogaria Venancio. DS Healthcare Expands Distribution Channels in Brazil Through Leading Rio de Janeiro Pharmacy Chain
GlobeNewswire - Wed Aug 06, 7:43AM CDT
DS Healthcare Group, Inc. (NASDAQ: DSKX), a leading developer of personal care products and specialty pharmaceuticals, announced today it has signed a distribution agreement with Drogaria Venancio, a leading Rio de Janerio-based pharmacy chain. Drogaria Venancio will sell DS Healthcare's clinically proven personal care products including its Revita and Spectral hair re-growth and hair care products. DS Laboratories, its flagship line can already be found on retail shelves throughout Rio de Janeiro. Drogaria Venancio operates wholesale distribution centers and premium retail pharmacy locations. Founded in 1979, the pharmacy chain employs 1600 people.
Global Anti-Aging Product Market 2014-2018 - Skincare Products, Cosmeceuticals, and Hair Care Products
M2 - Wed Jul 16, 8:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7slrvw/global_antiaging) has announced the addition of the "Global Anti-Aging Product Market 2014-2018" report to their offering. The Global Anti-aging Product market will grow at a CAGR of 6.77 percent over the period 2013-2018. Aging is associated with numerous common health problems. Anti-aging products help in fighting the various signs of aging or problems such as wrinkles, blemishes, dry lines, fine color, pores, graying, thinning, and sagging. To overcome these aging problems related to skin and hair consumers use many products that basically fall under three categories: skincare, cosmeceuticals, and hair care. The Global Anti-aging Product market can be divided into three segments: Skincare Products, Cosmeceuticals, and Hair Care Products. These are the product categories used by consumers to reduce various signs of aging and maintain youthfulness. The report, the Global Anti-aging Product Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Anti-aging Product market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Beiersdorf AG - L'Or?al SA - Phosphagenics Ltd. - Procter & Gamble Co. - Unilever Group Other Prominent Vendors - Allergan Inc. - Amexdrug Corp. - Avon Products Inc. - Chanel SA - Christian Dior SA - Clarins USA Inc. - DS Healthcare Group Inc. - Elizabeth Arden Inc. - Ella Bach? - Est?e Lauder Co. Inc. - Henkel AG & Co KGaA - Jan Marini Skin Research Inc. - Johnson & Johnson Co. - Kao Corp. - NeoStrata Co. - NuSKin Enterprises - Orlane SA - Revlon Inc. - Robanda International Inc. - Shiseido Co. - SkinMedica Inc. - Skinvisible Inc. - Woodridge Labs Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Demographic Segmentation - Market Segmentation by Product - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/7s..._antiaging
DS Healthcare Appoints Mark Wolfson to its Board of Directors
GlobeNewswire - Wed Jul 16, 7:00AM CDT
DS Healthcare Group, Inc.(NASDAQ: DSKX), a leading developer of personal care products and specialty pharmaceuticals, announced today that Mark Wolfson has joined its Board as an Independent Director and will serve on the Company's Audit Committee, and its Nominating and Corporate Governance Committee.
DS Healthcare Opens its First DS Laboratories Store in China
GlobeNewswire - Mon Jul 14, 7:00AM CDT
DS Healthcare Group, Inc. (NASDAQ: DSKX), a leading developer of personal care products and specialty pharmaceuticals, announced today that the first DS Laboratories store worldwide has opened in Shanghai, China in partnership with the Company's Chinese distributor. The store exclusively features a complete line of DS Healthcare products including the Company's clinically proven, industry-leading Spectral line of hair loss treatments and Revita hair stimulating shampoos and conditioners. The Company plans to open additional partnership stores worldwide in the coming months.
DS Healthcare Group to Open its First Retail Boutique as Part of Global Brand Strategy
GlobeNewswire - Thu Feb 27, 8:52AM CST
DS Healthcare Group, Inc. (NASDAQ: DSKX), a leading developer of personal care products, today announced it is in the process of opening its first DS Laboratories retail store scheduled to open in the third quarter of 2014. The store, to be located in the metro Miami area, will showcase DS Healthcare's line of products including its industry-leading Spectral line of hair loss treatments and Revita hair stimulating shampoo and conditioner. The move is part of the Company's broader strategy as it continues to build the premier global brand in clinically proven personal care products.
DS Healthcare Group Signs Agreement with Leading Global Healthcare Company
GlobeNewswire - Mon Feb 10, 7:02AM CST
DS Healthcare Group, Inc. (NASDAQ
SKX), a leading developer of personal care products, today announced it has signed an agreement with a global healthcare company that ranks in the top 200 of the Fortune Global 500 list of largest corporations in the world in 2013. Per the terms of the agreement, DS Healthcare is providing the formulation, ingredients and its technology to the global healthcare company for use in a topical product. The product is to be launched and distributed by the global healthcare company under their own brand following successful development. Under the terms of the agreement, DS Healthcare will act as the exclusive ingredient supplier for a period of 5 years, which will automatically renew under certain conditions. DS Healthcare Group Moves Prescription Hair Loss Treatment Forward with Appointment of Aptiv Solutions as CRO
GlobeNewswire - Mon Jan 27, 7:00AM CST
DS Healthcare Group, Inc. (NASDAQ
SKX), a leading developer of personal care products, today announced it has appointed Aptiv Solutions as its clinical research organization (CRO) for its proprietary topical prescription treatment. If approved the drug will be positioned as frontline therapy in the fight against hair loss, a condition that affects nearly half of the population. DS Healthcare Group Prepares to File Investigational New Drug Application with FDA for Prescription Hair Loss Treatment
GlobeNewswire - Thu Jan 09, 7:00AM CST
DS Healthcare Group, Inc.(NASDAQ
SKX), a leading developer of personal care products, today announced it is preparing to submit to the United States Food and Drug Administration (FDA) an Investigational New Drug Application (IND) for its proprietary topical hair loss treatment. On October 29, 2013 the Company had announced it filed a patent with the United States Patent and Trademark Office for the invention. An IND is a request for the FDA's authorization to administer an investigational drug to humans and is the first step towards designing and conducting clinical trials in the U.S. DS Healthcare is currently in late stage discussions with various clinical research organizations (CROs) to design and conduct clinical trials for its breakthrough hair loss treatment. DS Healthcare Group Inc concludes USD3.144m private placement
M2 - Tue Jan 07, 7:55AM CST
Personal care products company DS Healthcare Group Inc (Nasdaq
SKX) announced on Monday the sale of 1,965,000 common shares for gross proceeds of USD3.144m to a group of accredited investors in a securities purchase agreement. DS Healthcare Group Completes Private Placement of $3,144,000 Dollars
GlobeNewswire - Mon Jan 06, 7:01AM CST
DS Healthcare Group, Inc. (Nasdaq: DSKX), a developer of personal care products, today announced that it has completed its securities purchase agreement with a group of accredited investors for the sale of 1,965,000 shares of the Company's common stock, with gross proceeds of $3,144,000. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS) acted as the placement agent in connection with the offering.
DS Healthcare Group, Inc. to Present at the Aegis Capital Corporation 2013 Healthcare Conference
GlobeNewswire - Thu Sep 19, 11:30AM CDT
DS Healthcare Group, NASDAQ (DSKX) announced today that Daniel Khesin, DS Healthcare's CEO, will present at the at the Aegis Capital Corporation 2013 Healthcare Conference on Saturday, September 28, 2013 at 11:00 AM PDT. The conference will be held at the Encore at Wynn Las Vegas on September 26-28, 2013.
DS Healthcare Group Launches Brazilian E-Commerce Site to Support Sales Momentum in Fast Growing Beauty Market
GlobeNewswire - Wed Sep 11, 12:00PM CDT
DS Healthcare Group, Inc. (NASDAQ
SKX), a leading developer of personal care products, today announced it has launched its Brazilian website: http://dslabshop.com.br. The e-commerce site provides convenient online shopping for Brazilians. The site also offers extensive product information to support in-stores sales of its products. OTC Daily Alert Stock Watch - DS Healthcare Group, Inc., (NASDAQ: DSKX)
WorldStockWire - Fri Aug 30, 12:30AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
